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Background: Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, and metastasis occurs in up to
one-third of cases. However, the mechanisms of invasion and metastasis remain unclear. Tumour-associated macrophages
(TAMs) have important roles in tumour invasion, metastasis, and/or poor prognosis. The aim of this study was to investigate the
relationship between TAMs and MLS.
Methods: Using 78 primary MLS samples, the association between clinical prognosis and macrophage infiltration was evaluated
by immunochemistry. The effects of macrophages on cell growth, cell motility, and invasion of MLS cell lines were investigated
in vitro. In addition, clinicopathological factors were analysed to assess their prognostic implications in MLS.
Results: Higher levels of CD68-positive macrophages were associated with poorer overall survival in MLS samples. Macrophage-
conditioned medium enhanced MLS cell motility and invasion by activating epidermal growth factor receptor (EGFR), with the key
ligand suggested to be heparin-binding EGF-like growth factor (HB-EGF). The phosphoinositide 3-kinase/Akt pathway was mostly
involved in HB-EGF-induced cell motility and invasion of MLS. The expression of phosphorylated EGFR in MLS clinical samples
was associated with macrophage infiltration. In addition, more significant macrophage infiltration was associated with poor
prognosis even in multivariate analysis.
Conclusions:Macrophage infiltration in MLS predicts poor prognosis, and the relationship between TAMs and MLS may be a new
candidate for therapeutic targets of MLS.
Myxoid liposarcoma (MLS) is the second most common subtype
of liposarcoma, comprising B30% of all liposarcomas and about
10% of all adult soft tissue sarcomas (Antonescu and Ladanyi,
2013). The morphologic spectrum of tumours ranges from purely
myxoid tumours to the more aggressive highly cellular round cell
liposarcoma. Primary myxoid liposarcoma with more than a 5%
round cell component is associated with a poor clinical prognosis
(Antonescu et al, 2001; Oda et al, 2005). The most commonly
affected regions tend to be the deep compartments of the
extremities. Metastasis occurs in up to one-third of cases
and is characterized by a propensity to spread to unusual
extra-pulmonary locations (Haniball et al, 2011; Asano et al,
2012). However, the mechanism of tumour progression in MLS
remains unclear. Therefore, it is important to elucidate the
mechanism and to discover new prognostic factors and medical
treatment targets.
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Recent reports have shown that tumour malignancy is
dependent upon interactions in the tumour microenvironment
between tumour cells and stromal cells such as immune cells,
fibroblasts, and endothelial cells (Kamura et al, 2010; Pietras and
Ostman, 2010). In particular, tumour-associated macrophages
(TAMs) are stromal cells that are known to promote tumour
invasion, metastasis, and angiogenesis in various tumours
(Condeelis and Pollard, 2006; Qian and Pollard, 2010). Tumour-
associated macrophages produce and secrete growth factors,
cytokines, and other inflammatory mediators that may have
important roles in cancer progression (Condeelis and Pollard,
2006; Baay et al, 2011). These tumour-promoting functions are
consistent with clinical studies showing that high macrophage
density in many human cancer types is associated with increased
tumour angiogenesis and metastasis, and/or a poor prognosis.
In carcinomas, the majority of studies show that greater TAM
infiltration is associated with poor prognosis, suggesting that
TAMs may promote tumour progression (Leek et al, 1996;
Komohara et al, 2013). With regard to sarcomas, we previously
reported that TAM infiltration predicts poor prognosis in Ewing
sarcoma (Fujiwara et al, 2011). Lee et al (2008) reported that an
increased density of infiltrating macrophages was associated with
poor outcomes in non-gynaecologic leiomyosarcomas. In contrast,
Buddingh et al, (2011) showed that TAMs were associated with
reduced frequency of metastasis and improvement in overall
survival in. Thus, the role of TAMs in sarcomas differs depending
on sarcoma subtypes, and there are few findings regarding their
role in MLS. In this study, we investigated the role of TAMs in
MLS.
MATERIALS AND METHODS
Cell lines. The myxoid liposarcoma cell lines MLS1765 and
MLS402-91 were kindly provided by Dr Aman (Department of
Clinical Genetics, University Hospital, Lund, Sweden) (Aman et al,
1992). The murine macrophage RAW264.7 cell line was obtained
from the European Collection of Cell Cultures (Salisbury,
Wiltshire, England), and the human monocyte cell line U937
was obtained from the American Type Culture Collection
(Manassas, VA, USA). Cells were cultured in RPMI-1640
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (HyClone Laboratories, Inc., Logan, UT, USA), 100
units per ml penicillin, and 100 mgml 1 streptomycin at 37 1C in
an atmosphere of 5% CO2. To induce U937 differentiation into
macrophage-like cells, 10 ngml 1 phorbol 12-myristate 13-acetate
(Sigma-Aldrich, St Louis, MO, USA) dissolved in dimethyl
sulfoxide was added for 72 h, and lipopolysaccharide 1mgml 1
was added for an additional 48 h. In all, 1 106 cells from each cell
line were placed in 10-cm dishes. After cell adhesion, the medium
was changed to 10ml per well serum-free RPMI, and incubated for
24 h. The medium was collected and the cellular debris was pelleted
by centrifuging. The undiluted supernatant was used as the
conditioned medium (CM) of each cell line.
Reagents. Recombinant human HB-EGF and anti-HB-EGF anti-
bodies were purchased from R&D Systems (Minneapolis, MN,
USA). Gefitinib was purchased from Cayman Chemical (Ann
Arbor, MI, USA). Anti-EGF receptor antibody (D38B1) and anti-
phosphorylated EGF receptor (pEGFR) antibody (Tyr1068, D7A5)
were purchased from Cell Signaling Technology (CST; Danvers,
MA, USA). Anti-CD68 antibody was purchased from Dako
(Glostrup, Denmark). Anti-CD163 antibody was purchased from
Leica Biosystems (Newcastle, UK). PD98059, LY294002, and
U-73122 were purchased from Calbiochem (San Diego, CA, USA).
Clinical samples. The study protocol was approved by the
Institutional Review Board at Kyushu University. A total of 93
MLS cases that were diagnosed between 1981 and 2012 were
retrieved from the archives of the Department of Anatomical
Pathology, Graduate School of Medical Sciences, Kyushu Uni-
versity, Fukuoka, Japan. In each case, MLS was diagnosed on the
basis of histological features. All patients had been treated by
marginal or wide resection. Tissues were collected during primary
tumour biopsy or surgical resection; those obtained after radiation
or chemotherapy treatment were omitted. Of the 93 cases
identified, 15 were excluded, 4 because of lack of availability of
adequate tissue, and 11 because of lack of follow-up data. Thus, 78
patients were included in the present study. Clinical data were
obtained by reviewing patient records, and survival data were
collected during the winter of 2013. Each case was evaluated
according to the American Joint Committee on Cancer (AJCC)
grading system.
Immunohistochemistry. Whole-section samples were fixed in
10% neutral buffered formalin and embedded in paraffin, and the
sections were deparaffinised in xylene and rehydrated in ethanol.
Antigen was retrieved by microwave pretreatment with 10mM
citrate buffer (pH 6.0) for CD68 and CD163, and 1mM EDTA
buffer (pH 8.0) for pEGFR. After peroxidase blocking with
hydrogen peroxide, the sections were incubated with the following
primary antibodies: anti-CD68 (1 : 100, Dako) and anti-CD163
(1 : 100, Leica Biosystems) 1 h at room temperature and anti-
pEGFR (1 : 200, CST) overnight at 4 1C. EnVision System HRP
Labelled Polymer (Dako) was used as a secondary antibody. The
reaction products were visualized with 3-3 diaminobenzidine
tetrahydrochloride and counterstained with haematoxylin. Assess-
ment of macrophage number was performed by counting CD68-
positive cells and CD163-positive cells in 10 random high power
field (HPF) profiles. Expression of pEGFR was evaluated and
samples were classified as negative when there was either no
staining or weak staining in the cytoplasm and/or nucleus
compared with the stromal elements, and as positive when there
was moderate to strong staining. Images were acquired using an
AX70 microscope equipped with a DP72 camera (both from
Olympus Corp., Tokyo, Japan).
Double fluorescent immunohistochemistry. To identify the
co-expression of CD68 and CD163, double fluorescent immuno-
histochemical staining was performed in 10 different MLS clinical
samples. Tissue samples were deparaffinised, rehydrated, and
antigen was retrieved by microwave with 10mM citrate buffer
(pH 6.0). After blocking with normal goat serum for 1 h, the samples
were incubated with anti-CD68 (mouse IgG) and anti-CD163
(rabbit IgG, Santa Cruz) for 2 h. The reactions were visualised
using secondary fluorescently labelled antibodies including goat
anti-mouse Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 546
(both from Invitrogen Corp.), mounted in Vectashield mounting
medium containing DAPI (Vector Laboratories, Burlingame, CA,
USA), and imaged using BZ-X710 fluorescence microscopy
(Keyence Corp., Osaka, Japan).
Transwell migration assay. A migration assay was performed
using Transwell chambers (Corning Costar Corp., Cambridge, MA,
USA) as described previously (Kamura et al, 2010). In brief, MLS
cell lines or RAW264.7 cells (1.0 105 per well) were suspended in
100 ml serum-free RPMI and seeded in the upper chambers. The
lower chambers were placed in 600 ml serum-free RPMI containing
CM or the indicated growth factors, antibodies. The indicated
inhibitors were added to both upper and lower chambers.
RAW264.7 cells were permitted to migrate for 6 h, and MLS cells
migrated for 12 h. The cells that migrated to the lower side of the
filter were fixed and stained using a Diff-Quik kit (Sysmex, Kobe,
Japan), and counted by examining six fields per filter under a
microscope.
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Wound-healing assay. Wound-healing assays were performed as
described previously (Kamura et al, 2010). Confluent cell
monolayers in 35-mm dishes were wounded by scraping with a
micropipette tip. The cells were washed and then cultured in
serum-free RPMI containing CM or the noted reagents and
inhibitors. The degree of wound closure was assessed by measuring
the distance between the wound edges after 0 and 12 h.
Invasion assay. Invasion assays were performed using the Biocoat
Matrigel invasion chamber (BD Biosciences, Bedford, MA, USA) as
described previously (Harimaya et al, 2000). Myxoid liposarcoma
cell lines (1.0 105 per well) were suspended in 100 ml serum-free
RPMI and seeded in the Matrigel-coated upper chambers. The
lower chambers were placed in 600 ml serum-free RPMI containing
CM or the indicated growth factors and antibodies. The indicated
inhibitors were added to both upper and lower chambers. After
24-h incubation, the filters were fixed and the number of cells was
determined as described for the transwell migration assay.
Western blot analysis. Myxoid liposarcoma cells were stimulated
with macrophage-conditioned medium (M-CM: RAW-CM and
U937-CM) or HB-EGF 20 ngml 1 for 5min. To inhibit the
stimulation, various concentrations of gefitinib and anti-HB-EGF
antibody were added for 2 h before the stimulation. After
stimulation, the cells were lysed using CelLytic (Sigma-Aldrich)
with a protease and phosphatase inhibitor cocktail (Complete
Mini, PhosSTOP; Roche Diagnostics, Mannheim, Germany).
Western blot analysis was performed as described previously
(Fujiwara-Okada et al, 2013; Iida et al, 2013) with the following
primary antibodies: pEGFR (1 : 500), EGFR (1 : 1000), and b-actin
(1 : 2000, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
RNA preparation and PCR. Total RNA from MLS clinical
samples and cell lines was extracted using the Rneasy Lipid Tissue
Mini kit and Rneasy kit (Qiagen, Hilden, Germany), respectively.
PCR was performed as described previously (Fujiwara et al, 2011).
The primers are summarized in Supplementary Table S1.
Phospho-receptor tyrosine kinase analysis. Phosphorylated
receptor tyrosine kinases (RTKs) of MLS cell lines after stimulation
by M-CM were detected using the Human Phospho-RTK Array kit
(R&D Systems) according to the manufacturer’s instructions.
Myxoid liposarcoma cells were stimulated with or without M-CM
for 5min. The cell lysate was added to a nitrocellulose membrane
that contained 49 different anti-RTK antibodies printed in
duplicates, and incubated overnight at 4 1C. After washing, the
membrane was incubated with anti-phospho-Tyrosine-HRP for 2 h
at room temperature, and immunoreactivity was detected using
Chemi Reagent Mix.
EGFR signalling analysis. Phosphorylated downstream signalling
modules of EGFR after stimulation by HB-EGF were detected
using the PathScan EGFR Signaling Antibody Array kit (CST)
according to the manufacturer’s instructions. In brief, MLS cells
were stimulated with or without HB-EGF (20 ngml 1) for 5min.
The cell lysate was arrayed on a nitrocellulose-coated glass slide
which antibodies were spotted in duplicates, and incubated
overnight at 4 1C. After washing, the glass slide was incubated
with a detection antibody cocktail for 1 h and HRP-linked
streptavidin for 30min at room temperature, and immunoreactiv-
ity was then detected using Chemi Reagent Mix.
Statistical analysis. Survival curves were calculated using the
Kaplan–Meier method, and the log-rank test was used for survival
analysis. Fisher’s exact test was used to compare categorized
variables. The hazard ratios for risk factors for death were
evaluated using the Cox proportional hazards regression model.
The Student’s t-test was used for two-group comparisons. Po0.05
was considered as statistically significant. Data in graphs are given
as mean±s.d. All data analysis was performed using a statistical
software package (JMP9, SAS Institute Inc., Cary, NC, USA).
RESULTS
Infiltrating macrophages into MLS associated with poor clinical
outcome. To investigate whether infiltrating macrophages were
associated with clinical outcome in patients with MLS, anti-CD68
antibodies were used to quantify the number of macrophages in 78
primary MLS clinical samples (Figure 1A). Clinicopathological data
are summarized in Supplementary Table S2. Kaplan–Meier survival
analysis was performed to determine the prognostic significance of
macrophages, and showed that greater macrophage infiltration
(X100 CD68 cells/10 HPF) was associated with poorer overall
survival (P¼ 0.0002, Figure 1B). Macrophages have a wide
phenotypic diversity and can be classified into two activation
phenotypes, M1 and M2 (Goerdt and Orfanos, 1999). Classically,
M1 macrophages are pro-inflammatory and can exert cytotoxic
activity. In contrast, M2 macrophages are anti-inflammatory and
promote angiogenesis and tissue remodelling. Tumour-associated
macrophages often exhibit features of M2 macrophages and produce
a number of cytokines and growth factors that promote tumour
progression. To evaluate the M2 phenotype in infiltrating macro-
phages, we performed immunostaining with antibodies against
CD163, a marker of M2 macrophages (Figure 1A), as well as
Kaplan–Meier survival analysis (Figure 1B). Co-expression of CD68
and CD163 was assessed by double fluorescent immunohistochemical
staining (Figure 1C). Higher levels of CD163-positive macrophages
were also associated with poorer overall survival (P¼ 0.0213,
Figure 1B). On the basis of these results, we suggest that a high
percentage of the TAMs in MLS are M2 macrophages, and we
hypothesized that MLS might have the ability to recruit
macrophages that have a role in the malignant transformation in
MLS. To investigate the potential mechanisms underlying recruit-
ment of macrophages to MLS, a Transwell migration assay was
performed. Myxoid liposarcoma cell line-conditioned medium
(MLS-CM) significantly promoted cell migration of RAW264.7
cells, a murine macrophage cell line (Figure 1D), suggesting that
the factors that promote macrophage recruitment were contained
in MLS-CM. Next, expression profiles of cytokines and chemo-
kines secreted by MLS cells were examined using the Luminex
multiplex assay system. Remarkably, CCL2, CCL5, CXCL8, and
VEGF, which are known to stimulate monocyte chemotaxis (Carr
et al, 1994; Matsumoto et al, 2002), were secreted in MLS-CM
(Supplementary Figure S1). Therefore, these MLS-secreted cyto-
kines and chemokines are likely to be critical factors in recruiting
macrophages into the tumour microenvironment of MLS.
Macrophages upregulated the motility and invasion of MLS cells
by phosphorylation of EGFR. To elucidate the role of TAMs in
the development and progression of MLS, we first performed a cell
proliferation assay to measure the effect of RAW264.7 and U937
macrophages on the growth of MLS cells. The presence of M-CM
did not affect MLS cell growth (Supplementary Figure S2). Next,
we investigated the effect of M-CM on motility of MLS cells via
Transwell migration assay and wound-healing assay. M-CM
significantly upregulated chemotaxis and chemokinesis of MLS
cells (Figure 2A and B). We also found that M-CM significantly
promoted MLS cell invasion (Figure 2C), an important result as
cell motility is a critical factor in tumour cell invasion. One of the
mechanisms known to upregulate cell motility is activation of the
RTK pathway (Hubbard and Miller, 2007). We used a phospho-
RTK antibody array to determine which RTKs were activated in
M-CM-stimulated MLS cells. Of 49 MLS cell RTKs, only EGFR
was phosphorylated by M-CM (Figure 2D), which was also
confirmed by western blot (Figure 2E; Supplementary Figure S3).
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Gefitinib, a tyrosine kinase inhibitor of EGFR, dose-dependently
reduced M-CM-induced EGFR phosphorylation and also signifi-
cantly suppressed MLS cell motility (Figure 2E and F;
Supplementary Figure S3). These data suggested that activation
of EGFR by macrophages could have a critical role in MLS motility.
To investigate the correlation between macrophage infiltration and
activation of EGFR in MLS, MLS clinical samples were
immunostained with anti-pEGFR (Figure 2G and H). Twenty-
seven cases (35%) were positive and fifty-one cases (65%) were
negative. The results of immunostaining with anti-CD68 and anti-
pEGFR clearly demonstrated that greater macrophage infiltration
was significantly associated with positive pEGFR (odds ratio, 8.07;
95% confidence interval, 2.25–28.97; P¼ 0.0016) (Figure 2I). In
addition, greater macrophage infiltration was also significantly
associated with metastasis (odds ratio, 16.85; 95% confidence
interval, 4.02–70.57; P¼ 0.0001) and higher AJCC stage (odds
ratio, 6.67; 95% confidence interval, 1.68–26.39; P¼ 0.0072)
(Supplementary Table S3).
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Figure 1. Association between macrophage infiltration and poor prognosis in MLS. (A) Immunohistochemical staining of human MLS sections
using anti-CD68 and anti-CD163 antibodies. Upper panel shows cases with higher levels of macrophage infiltration (left,X100 CD68 cells/10 HPF;
right,X80 CD163 cells/10 HPF), and lower panel demonstrates cases with lower levels of macrophage infiltration (left,o100 CD68 cells/10 HPF;
right, o80 CD163 cells/10 HPF). Scale bars: 20mm. (B) Kaplan–Meier survival curves for overall survival of all patients based on CD68-positive
(upper) and CD163-positive (lower) macrophage infiltration. Log-rank test was performed to determine statistical significance, with Po0.05
defined as significant. (C) Co-expression of CD68 and CD163 in MLS clinical samples. Sections were immunostained for CD68 (green) and CD163
(red). Nuclei were visualized using DAPI (blue). Scale bar: 10mm. (D) Migration of macrophages was examined using the Transwell system.
The lower wells were filled with serum-free medium or medium conditioned by MLS1765 or MLS402-91, and RAW264.7 cell migration to the
bottom surface of the Transwell was assessed. Results are presented as mean±s.d. ***Po0.001 vs control.
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HB-EGF secreted by macrophages was a key ligand in activating
EGFR of MLS cells. Another important issue was identifying
which EGFR ligands were dominant in M-CM-induced motility
of MLS cells. The major ligands of EGFR are EGF, HB-EGF,
transforming growth factor-a (TGFa), amphiregulin (AREG),
epiregulin (EREG), epigen (EPGN), and betacellulin (BTC). Of
these, HB-EGF and AREG were commonly expressed in
RAW264.7 and U937 (Figure 3A). Importantly, HB-EGF
significantly upregulated MLS cell motility (Figure 3B and C)
and invasion (Figure 3D). In contrast, AREG did not promote
MLS cell motility (Supplementary Figure S4). Anti-HB-EGF-
neutralizing antibody inhibited the M-CM-induced motility of
MLS cells and reduced their M-CM-induced EGFR phosphor-
ylation (Figure 3E–G; Supplementary Figure S5). In contrast,
anti-AREG neutralizing antibody had no effect on M-CM-
induced cell motility (Supplementary Figure S4). Taken together,
these results showed that macrophage-secreted HB-EGF was the
key ligand in activating EGFR of MLS cells, and it strongly
enhanced MLS cell motility and invasion. In addition, the
expression of EGFR ligands in MLS clinical samples was
evaluated by RT-PCR (Figure 3H). Among 10 MLS clinical
samples, HB-EGF was the most commonly expressed ligand
(90%), suggesting a clinical role of HB-EGF in the progression
of MLS.
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The PI3K/Akt pathway was the key downstream signalling
pathway in HB-EGF-induced motility of MLS cells. Activated
EGFR stimulates a wide range of signalling modules, including
PI3K/Akt, mitogen-activated protein kinase (MAPK) cascade,
phospholipase C (PLC) g, and signal transducer and activator of
transcription 3 (STAT3). The PathScan EGFR Signalling Antibody
Array was used to accurately detect the activated EGFR-stimulated
downstream signalling modules in HB-EGF-induced MLS cells.
HB-EGF stimulated EGFR, MEK1/2, Erk1/2, Akt, and PLCg
(Figure 4A). STAT3 was not phosphorylated by HB-EGF
stimulation. To identify the dominant downstream EGFR signal-
ling pathway required for HB-EGF-induced cell motility, we used
various pharmacological inhibitors, including LY294002 for PI3K/
Akt, PD98059 for MEK and Erk, and U-73122 for PLCg.
LY294002, but not PD98059 or U-73122, remarkably suppressed
HB-EGF-induced migration of MLS cells (Figure 4B). These results
confirmed that the HB-EGF-EGFR-PI3K/Akt axis was the
dominant pathway involved in the HB-EGF-induced motility of
MLS cells.
Macrophage infiltration is a prognostic factor in MLS. Finally,
we investigated in detail the prognostic significance of macro-
phage infiltration into MLS. Univariate and multivariate analyses
were performed using the following variables: number of CD68
cells, age, sex, location, tumour size, and round cell component
(Table 1). Phosphorylated EGFR, metastasis, and AJCC stage
were excluded because of their strong association with the
number of CD68 cells. In univariate analysis, the number of
CD68 cells and sex were significantly associated with poor
prognosis. Multivariate analysis revealed that only the number of
CD68 cells was an independent and significant factor for poor
prognosis.
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chemotaxis of MLS1765 and MLS402-91 cells was assessed by Transwell migration assay with various concentrations of HB-EGF added to the
lower chamber. Data are depicted as mean±s.d. ***Po0.001 vs HB-EGF 0ngml 1. (C) Wound-healing assay was performed to assess the
chemokinesis of MLS cells treated with HB-EGF (20 ngml1) for 12 h. Data are shown as mean±s.d. **Po0.01, ***Po0.001. (D) Invasion of MLS
cells in response to HB-EGF (20 ngml 1) was assessed by invasion assay. Data are depicted as mean±s.d. ***Po0.001. (E) The effect of anti-HB-
EGF–neutralizing antibody on macrophage-CM-induced motility of MLS1765 cells was assessed by Transwell migration assay. Anti-HB-EGF
antibody (10 mgml 1) or normal IgG was added to lower chamber. Data are shown as mean±s.d. **Po0.01, ***Po0.001. (F) The effect of anti-
HB-EGF-neutralizing antibody on macrophage-CM-induced phosphorylation of EGFR in MLS1765 cells was assessed by western blot analysis with
anti-EGFR and anti-pEGFR antibodies. Actin was used as a loading control. (G) Invasion assay was performed to assess the effect of anti-HB-EGF-
neutralizing antibody on macrophage-CM-induced invasion. Data are depicted as mean±s.d. *Po0.05, **Po0.01, ***Po0.001. (H) The
expression profiles of EGFR ligands from 10 MLS clinical samples were detected by RT-PCR. GAPDH was used as an internal control.
P, positive control.
BRITISH JOURNAL OF CANCER The roles of TAMs in MLS
552 www.bjcancer.com |DOI:10.1038/bjc.2014.637
DISCUSSION
Metastasis occurs in up to one-third of MLS cases, and causes
unfavourable outcomes. Tumour-associated macrophages have
important roles in tumour invasion and metastasis (Condeelis and
Pollard, 2006), and infiltration of TAMs into tumours results in
tumour progression and poor prognosis. The presence of a high
number of TAM is associated with various types of tumours,
including bone and soft tissue tumours (Komohara et al, 2013). We
previously reported that higher TAM infiltration was associated
with poor prognosis in Ewing sarcoma (Fujiwara et al, 2011). In
this study, we showed that greater TAM infiltration was associated
with poor prognosis in MLS (Figure 1B), and its prognostic
importance was confirmed in multivariate analysis (Table 1). On
the basis of these results, TAMs are potentially a new prognostic
factor for MLS. To our knowledge, this is the first report
demonstrating an association between poor MLS prognosis and
the role of TAMs.
In order for metastasis to occur, tumour cells must invade the
extracellular matrix to separate from the primary lesion, intravasate
to circulate towards distant organs, and then extravasate and engraft.
In this study, we showed that macrophages promoted cell motility
and invasion of MLS cells (Figure 2A–C). Furthermore, greater
TAM infiltration was significantly correlated with the presence of
metastasis (Supplementary Table S3). These results suggest that
TAMs may have an important role in invasion and metastasis of
MLS, especially during the first step involving dispatch from the
primary lesion and intravasation. On the contrary, roles of TAMs in
the later stages in MLS metastasis, such as during extravasation and
homing to target organs, remain obscure. Thus further investigation,
including in vivo experiments, is required.
It will be beneficial and interesting to define the mechanisms
involved in TAM-induced motility and invasion of MLS cells. One
possible mechanism is activation of the RTK pathway in MLS,
since various RTKs, such as MET, IGF-1R, PDGFR, and EGFR,
have been identified in MLS (Cheng et al, 2009; Negri et al, 2010).
In MLS cells in this study, only EGFR, and not MET, IGF-1R, or
PDGFR, was phosphorylated by M-CM in vitro (Figure 2D).
Importantly, greater TAM infiltration in MLS was associated with
higher expression of pEGFR in clinical samples (Figure 2I). These
results offer solid evidence that TAMs enhance invasion and
metastasis of MLS by activating the EGFR signalling pathway.
Identifying the key factors involved in TAM-induced activation
of EGFR in MLS is the next important task that should be
undertaken. Heparin-binding EGF-like growth factor is a member
of the EGF family of molecules, which has a role in wound healing,
cardiac hypertrophy, and heart development and function (Nanba
and Higashiyama, 2004). In cancer, HB-EGF can contribute to
tumour aggressiveness, including tumour proliferation, invasion,
and metastasis, and there is growing evidence of the association
between HB-EGF expression and poor cancer prognosis
(Miyamoto et al, 2006). High expression of HB-EGF has also
been detected in some soft tissue sarcomas and it is significantly
associated with poor overall survival (Hoffmann et al, 2009).
Furthermore, recent reports have shown that HB-EGF secreted by
macrophages is a key factor in tumour progression in breast cancer
(Vlaicu et al, 2013) and colon cancer (Rigo et al, 2010). In this
study, we showed that HB-EGF enhanced migration and invasion
of MLS cells via strong activation of EGFR (Figure 3B–F). On the
basis of our findings and those of previous reports, we propose that
HB-EGF is an important factor in TAM-induced invasion,
metastasis, and activation of the EGFR pathway. Of the EGFR-
stimulated downstream signalling modules in MLS, HB-EGF
activated MEK1/2, Erk1/2, Akt, and PLCg, but not STAT3
(Figure 4A). In this study, we confirmed that PI3K/Akt was the
key pathway in MLS (Figure 4B). This result corresponded the
previous findings that activation of PI3K/Akt pathway is associated
with tumour survival, invasion, and poor prognosis in a variety of
tumours (Engelman, 2009). In MLS, Demicco et al (2012)
demonstrated that activation of the PI3K/Akt pathway was
significantly associated with round cell change. Thus, HB-EGF
secreted by TAMs in MLS might be one of the critical factors in
activating the PI3K/Akt pathway that drives round cell transfor-
mation of MLS cells, therefore resulting in poor prognosis. This
notion is intriguing, however, we were not able to confirm the
association between macrophage infiltration and the round cell
component in this study. Therefore, further studies are required to
better understand the role of TAMs during the progression from
myxoid to round cells.
From the findings of this study, we consider TAMs and HB-
EGF to be potential molecular targets for treatment of MLS. In
particular, CRM197, a non-toxic mutant of diphtheria toxin and a
specific inhibitor of HB-EGF, has shown anticancer efficacy in
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Figure 4. The PI3K/Akt pathway was a key downstream signalling
pathway in HB-EGF-induced motility of MLS cells. (A) Analysis of
EGFR-stimulated intracellular signalling modules using PathScan EGFR
Signalling Antibody Array system. MLS1765 and MLS402-91 cell lysates
either treated or not treated with HB-EGF (20 ngml 1) for 5min were
assessed. Each antibody was spotted in duplicate. (B) The effects of
each inhibitor on HB-EGF-induced motility of MLS1765 cells were
assessed using a Traswell migration assay with HB-EGF (20 ngml1).
HB-EGF was added to the lower chambers and each inhibitor was
added to upper and lower chambers at the same time. Data are shown
as mean±s.d. ***Po0.001, #not significant.
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ovarian cancer both in vitro and in vivo, and clinical trials are now
underway. Because this study confirmed the expression of HB-EGF
in clinical samples of MLS as well as the biological effects of HB-
EGF on malignant phenotypes of MLS cells (Figure 3), MLS could
be a promising candidate for anti-HB-EGF agents.
In conclusion, the present study showed that macrophage
infiltration predicted poor prognosis in MLS, and a possible
underlying mechanism is that HB-EGF secretion by macrophages
enhanced MLS cell motility and invasion by activating EGFR. The
HB-EGF-EGFR-PI3K/Akt downstream signalling pathways had a
dominant role in TAM-induced cell motility and invasion of MLS.
Tumour-associated macrophages, HB-EGF, EGFR, and PI3K/Akt
could be new candidates for therapeutic targets of MLS and thus
further investigation is warranted.
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